Last week's 6 stocks (Lingyi Zhizao ~ Zhongke Wenge) can be played together with today's 4, but last Thursday's 3 stocks (Haiguang ~ Libang) cannot; a decision needs to be made!

Laifu Harmonic$LAIFUAL(03952.HK), standard robot components (harmonic reducer + joint module + robotic arm). Revenue was 100 million in the past two years, expected to reach 260 million in '25. Increment comes from reducer (+50%), joint volume ramp-up, and new robotic arm business. Growth aligns with the industry. Reducer price decline focuses on the second/third growth curves, but gross margin is lower than peers. IPO size 7.9-8.8 billion HKD, full circulation, almost eligible for Stock Connect. 18C shares at most 27k, not a lot. Cornerstone quality is average.

Xunlong Technology$XUNLONG SCITECH(06715.HK) , the largest caviar company, holds 30-40% global market share. Overseas-driven revenue, stable performance with increasing revenue and profit, mainly OEM for European and American caviar brands. Own brand shows little growth (increase overseas, decrease domestically). Gross margin stable. Domestic aquaculture processing companies are small and can't compare. Theme not very hot. 8.2 billion HKD full circulation, a small push could make it Stock Connect eligible. Shares 16k. Cornerstone quality is top-tier.

Zhenjiankang Medical$TH MEDICAL-B(02697.HK) , percutaneous puncture/ablation surgical robot, commercialized as early as '22, but initial penetration was through free trial installations. Performance only 1.8 million in '24 and 12.18 million in '25. Percutaneous surgical robot market is not particularly large, far smaller than orthopedics and laparoscopy. Valuation cannot match Jingfeng/Weichuang. Also in early stage + domestic challenges like difficult billing and approval for equipment. IPO size 4.2-4.8 billion HKD full circulation, no cornerstone. If made Stock Connect eligible, might be overvalued. Shares 18k. Speculative.

Jiangxi Biological$JIANGXI BIO(06915.HK) , human tetanus antitoxin (TAT), number one in China/globally, domestic market share 41% is high. After volume procurement, prices actually rose, indicating strong bargaining power with no competition. Average selling price and gross margin both increased. Export price is 1/3 of domestic, mainly targeting Southeast Asia and Africa due to lower purchasing power + market capture. In short, domestic sales stable relying on price increases, overseas price stable relying on volume growth. But overall growth only 10%, not particularly impressive. Other pipelines like antivenom serum show little growth, anti-rabies serum still early stage. IPO size 2.8-4.0 billion HKD full circulation, pure small cap. 7k shares, very few.